HC Wainwright reissued their buy rating on shares of Mirati Therapeutics (NASDAQ:MRTX) in a research report released on Tuesday, November 14th. HC Wainwright currently has a $17.00 price target on the biotechnology company’s stock, down from their previous price target of $20.00.
Other equities analysts have also issued research reports about the stock. Citigroup reaffirmed a buy rating and set a $16.00 price objective (up previously from $8.00) on shares of Mirati Therapeutics in a research report on Tuesday, September 19th. SunTrust Banks reiterated a buy rating and set a $13.00 price target on shares of Mirati Therapeutics in a report on Monday, October 2nd. Zacks Investment Research upgraded Mirati Therapeutics from a sell rating to a hold rating in a report on Tuesday, November 7th. Jefferies Group set a $5.00 price objective on shares of Mirati Therapeutics and gave the stock a hold rating in a research note on Friday, August 4th. Finally, Leerink Swann raised their price objective on shares of Mirati Therapeutics from $7.00 to $9.00 and gave the stock a market perform rating in a research note on Friday, September 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. Mirati Therapeutics currently has an average rating of Buy and a consensus target price of $13.71.
Mirati Therapeutics (MRTX) traded down $0.40 during mid-day trading on Tuesday, reaching $16.75. 361,354 shares of the company’s stock were exchanged, compared to its average volume of 515,987. Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $19.25.
In related news, SVP Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $14.00, for a total value of $104,986.00. Following the completion of the sale, the senior vice president now directly owns 10,169 shares in the company, valued at $142,366. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Venbio Select Advisor Llc bought 650,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were bought at an average price of $13.00 per share, with a total value of $8,450,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 23,544 shares of company stock valued at $365,826. Company insiders own 5.10% of the company’s stock.
Several institutional investors have recently bought and sold shares of MRTX. KCG Holdings Inc. acquired a new position in shares of Mirati Therapeutics during the 1st quarter worth about $106,000. Susquehanna International Group LLP grew its position in shares of Mirati Therapeutics by 46.5% during the 2nd quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after buying an additional 16,030 shares during the period. PDT Partners LLC acquired a new position in shares of Mirati Therapeutics during the 2nd quarter worth about $200,000. LMR Partners LLP acquired a new position in shares of Mirati Therapeutics in the 2nd quarter valued at approximately $236,000. Finally, Citadel Advisors LLC acquired a new position in shares of Mirati Therapeutics in the 3rd quarter valued at approximately $268,000. Institutional investors own 64.73% of the company’s stock.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with our FREE daily email newsletter.